Charles River Laboratories (NYSE: CRL) reported Q1 EPS of $1.40, $0.02 better than the analyst estimate of $1.38. Revenue for the quarter came in at $604.6 million versus the consensus estimate of $595.66 million.

• The Company is reaffirming its revenue growth and non-GAAP earnings per share guidance for 2019 including the acquisition of Citoxlab. In addition, the Company is providing initial GAAP earnings per share guidance including the acquisition of Citoxlab of $4.75 to $4.90. The Company is also providing initial free cash flow guidance including the acquisition of Citoxlab of $310 to $320 million.

• Non-GAAP EPS estimate $6.40 - $6.55

For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.